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Abstract
 
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) charac-
terized by plaques of infiltrating CD4
 
 
 
 and CD8
 
 
 
 T cells. Studies of MS and experimental au-
toimmune encephalomyelitis (EAE), an animal model of MS, focus on the contribution of
CD4
 
 
 
 myelin-specific T cells. The role of CD8
 
 
 
 myelin-specific T cells in mediating EAE or
MS has not been described previously. Here, we demonstrate that myelin-specific CD8
 
 
 
 T
cells induce severe CNS autoimmunity in mice. The pathology and clinical symptoms in
CD8
 
 
 
 T cell–mediated CNS autoimmunity demonstrate similarities to MS not seen in myelin-
specific CD4
 
 
 
 T cell–mediated EAE. These data suggest that myelin-specific CD8
 
 
 
 T cells
could function as effector cells in the pathogenesis of MS.
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Introduction
 
Multiple sclerosis (MS)
 
*
 
 is a demyelinating disease of the
central nervous system (CNS) of unknown etiology that is
characterized by a wide spectrum of neurological symptoms
(1). Clinical problems in MS patients frequently result from
upper motor neuron disease and include hyperreflexia,
ataxia, spasticity, and visual defects (2). MS is believed to be
an autoimmune disease because inflammatory infiltrates of
the CNS contain T and B lymphocytes (3–5) and because
genetic susceptibility has been linked to MHC class II genes
(6). In addition, experimental autoimmune encephalomy-
elitis (EAE), an animal model of MS, is induced by generat-
ing T cell–mediated immunity to myelin antigens.
Oligoclonal CD4
 
 
 
 and CD8
 
 
 
 T cell populations have
been detected within MS plaques, however, the function
and antigenic specificity of these T cells is not known (7,
8). Attention has focused on CD4
 
 
 
 T cells because suscep-
tibility to MS is associated with MHC class II genes (9–11)
and CD4
 
 
 
 T cells are critical to induction of EAE. In addi-
tion, a subset of TCR V gene sequences detected within
MS plaques have been reported to express TCR sequence
motifs similar to peripheral CD4
 
 
 
 T cells specific for my-
elin basic protein (MBP; reference 7). CD4
 
 
 
 T cells may
not be the only cells that mediate MS pathology, however,
as depletion of CD4
 
 
 
 T cells in MS patients made only
minor improvements in relapse rates or levels of MRI ac-
tivity (12, 13).
We chose to investigate the role of CD8
 
 
 
 T cells in CNS
autoimmunity for several reasons. First, CD8
 
 
 
 T cell clones
specific for myelin antigens have been isolated from the pe-
riphery of MS patients and normal donors (14, 15). Second,
MHC class I genes are in linkage disequilibrium with the
MHC class II genes associated with susceptibility to MS
(16). Third, the ability of CD8
 
 
 
 myelin-specific T cells to
function as effector cells in CNS autoimmunity has not
been investigated. Earlier studies of EAE in CD8-deficient
mice suggested that CD8
 
 
 
 T cells with undefined antigen
specificity may function as suppressor/regulatory T cells in
CNS autoimmune disease (17–19). CD8
 
 
 
 T cells derived
from rodents fed MBP also suppress in vitro immune re-
sponses to MBP and protect animals from induction of EAE
via a TGF-
 
 
 
–mediated pathway (19). Here we show that
MBP-specific CD8
 
 
 
 T cells isolated from wild-type mice
do not function as regulatory T cells but instead mediate se-
vere CNS autoimmunity. The disease induced by CD8
 
 
 
MBP-specific T cells exhibits some similarities to MS not
seen in myelin-specific CD4
 
 
 
 T cell–mediated EAE.
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Abbreviations used in this paper:
 
 CNS, central nervous system; EAE,
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eosin; LFB, Luxol Fast Blue; MBP, myelin basic protein; MBP–CTL,
CD8
 
 
 
 T cells specific for MBP; MS, multiple sclerosis; Vac–CTL, Vac-
cinia-specific CTLs. 
670
 
Myelin-specific CD8
 
 
 
 T Cells Induce CNS Autoimmunity
 
Materials and Methods
 
Mice.
 
C3HeB/FeJ, C3HeB/FeJ-MBP
 
shi/
 
 
 
, C3HeB/FeJ-
 
lpr
 
,
and C3HSmn.C-
 
scid
 
/J were purchased from The Jackson Labo-
ratory. All mice were housed in a specific pathogen free animal
facility at the University of Washington. All procedures have
been approved by the animal care and use committee of the Uni-
versity of Washington.
 
Peptides.
 
HPLC-purified MBP79-87 peptide was purchased
from Research Genetics.
 
Immunization and Isolation of MBP-specific T Cell Clones.
 
4–6-wk-old C3H and C3H.
 
shi
 
 mice were immunized in the
flank with 50 
 
 
 
g MBP79-87 peptide emulsified in Complete
Freund’s adjuvant. Draining lymph nodes from four immunized
C3H and C3H.
 
shi
 
 mice were harvested 10 d later and 3 
 
 
 
 10
 
7
 
draining lymph node cells were restimulated in vitro with 10
 
7
 
MBP 79–87-pulsed splenocytes and 10 U/ml IL-2 (Hoffman-La
Roche) in 10 mls RPMI supplemented with 10% FCS. After
1 wk in culture, T cell lines were cloned by limiting dilution by
culturing 10
 
4
 
, 10
 
3
 
, and 10
 
2
 
 T cells with 10
 
6
 
 syngenic spleen cells,
10
 
4
 
 L cells infected with Vaccinia virus expressing MBP, and 50
U/ml IL-2 per well in 200 
 
 
 
l final volume. T cell clones from
positive wells were then restimulated, expanded in 24-well plates,
and tested in a 
 
51
 
Cr release assay (20).
 
Flow Cytometry.
 
T cell clones were stained with FITC-
labeled anti-TCR-
 
  
 
, biotin-conjugated anti-CD8, and PE-
labeled anti-CD4 mAbs (BD PharMingen). Biotin-conjugated
anti-CD8 was visualized with streptavidin-conjugated Tricolor
(Caltag). Data were collected on a FACScan™ (Becton Dickinson)
and analyzed using CELLQuest™ software (Becton Dickinson).
 
T Cell Adoptive Transfers.
 
For disease induction experiments
using intravenous transfer of MBP–CTL, recipient mice were
sublethally irradiated (400 rads) on day 
 
 
 
1. 2 
 
 
 
 10
 
7
 
 T cells that
had been stimulated for 2 d in vitro were transferred intrave-
nously on day 0. 10
 
4
 
 U IL-2 were administered intraperitoneally
at the time of T cell transfer. For disease induction experiments
using intrathecal transfer, 10
 
6
 
 T cells were transferred (4 d after
in vitro stimulation) with or without neutralizing reagents in-
trathecally into T4/5 lumbar section of the spinal cord of recipi-
ent mice in 20 
 
 
 
l PBS. An additional dose of neutralizing re-
agents was intrathecally injected on day 1. Cytokine blocking
experiments used 40 ng of anti–IFN-
 
 
 
 (Clone H22, provided by
Dr. R. Schreiber) or hamster IgG anti-TNP (BD PharMingen);
100 ng TNFR:Fc (Immunex) or human IgG1 (Sigma-Aldrich)
per injection.
 
Clinical Scoring Scale for CTL-induced CNS Autoimmu-
nity.
 
Clinical scoring scale for CTL-induced CNS autoimmu-
nity was as follows. Grade 1, ataxia, loss of coordinated move-
ment, and spastic reflexes seen in only one rear leg, with spinning
and head-tilt in some mice; Grade 2, a loss of coordinated move-
ment and spastic reflexes of both rear legs; Grade 3, paralysis of
one leg (frequently sensation is retained); Grade 4, paralysis in
two legs (frequently sensation is retained); and Grade 5, mori-
bund. All Grade 5 mice were killed.
 
Histologic Analysis of Brain and Spinal Cords.
 
Brain and spinal
cord of 15 recipient mice of MBP–CTL (affected) and eight re-
cipient mice of VAC-CTL (control) were dissected, fixed in 10%
Millonig’s modified phosphate-buffered formalin for 48 h, sec-
tioned, and embedded in paraffin. To ensure reproducibility, a
rodent brain matrix (Electron Microscopy Sciences) was used for
all brain sectioning. 4–6 serial sections of five brain cross-sections
(20–30 total sections), two cross-sections of the spinal cord (T2,
L2) and three longitudinal sections (C1-6, T3-13, L3-cauda
equina) per mouse were stained with hematoxylin and eosin
(H&E), Luxol Fast Blue (LFB), Crystal Violet, and anti-GFAP
(Vector Laboratories). Sections from other major organs from
these mice were stained with H&E.
 
Results
 
MBP-specific CD8
 
 
 
 T Cells Circulate in the Periphery in
Wild-Type Mice.
 
Previously we demonstrated that MHC
class I–restricted, MBP-specific CD8
 
 
 
 T cells can be iso-
lated from C3H.
 
shi
 
 (MBP-deficient) mice primed with re-
combinant virus encoding MBP (20). The CD8
 
 
 
 CTLs are
specific for a single epitope, MBP79-87, associated with
the K
 
k
 
 MHC molecule. In this study MBP79-87–specific T
cells were not readily detected in primary T cell lines de-
rived from C3H wild-type mice infected with virus ex-
pressing MBP. This observation indicated that the MBP79-
87–specific T cells normally undergo substantial tolerance
induction in vivo, similar to many T cells specific for MHC
class II–restricted myelin epitopes (21–24).
To determine whether some MBP-specific CTLs escape
tolerance, we immunized wild-type C3H and MBP-defi-
cient C3H.
 
shi
 
 mice with MBP79-87 peptide and cloned T
cells from the draining lymph nodes by limiting dilution.
Six independent MBP-specific T cell clones were estab-
lished from C3H wild-type mice and 10 T cell clones were
established from C3H.
 
shi
 
 mice using this protocol. All T
cell clones derived from C3H and C3H.
 
shi
 
 mice were of
the CD8
 
 
 
/
 
 
 
 
 
 TCR 
 
 
 
/
 
 
 
 
 
 lineage (Fig. 1 A and data not
shown). All wild-type clones lysed H-2K
 
k
 
 expressing,
MHC class II–deficient target cells infected with recombi-
nant vaccinia virus encoding MBP as well as target cells
coated with MBP79-87 peptide in a similar dose-depen-
dent manner as T cell clones derived from C3H.
 
shi
 
 mice
(Fig. 1, B and C). These data indicate that CD8
 
 
 
 MHC
class I–restricted MBP-specific cytotoxic T cells circulate in
the periphery of wild-type mice and exhibit the same sensi-
tivity to antigen as T cells from MBP-deficient mice.
 
MBP-specific CD8
 
 
 
 T Cells Induce CNS Autoimmunity.
 
To investigate whether CD8
 
 
 
 T cells could induce CNS
autoimmunity, activated MBP-specific CD8
 
 
 
 T cell clones
isolated from C3H wild-type mice (MBP-CTLs) were
transferred intravenously into recipient mice. Both C3H
wild-type and C3H.
 
scid
 
 recipient mice exhibited pro-
nounced neurological disease. The clinical symptoms were
primarily associated with upper motor neuron impairment
including ataxia, spastic reflexes, loss of coordinated move-
ment, spinning, and head-tilt, with some mice developing
hind limb paralysis. Mice often lost motor function in their
hind legs yet retained sensory feelings. Because the clinical
disease course is distinct from classic EAE in which the pri-
mary symptom is ascending flaccid paralysis, we developed
a new scale for scoring the severity of clinical signs (see
Materials and Methods). The disease course was rapid and
severe in both wild-type and C3H.
 
scid
 
 mice, with signifi-
cant weight loss and a high incidence of mortality observed 
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(Fig. 2). Wild-type mice receiving vaccinia-specific CTLs
or C3H.
 
shi
 
 
 
/
 
 
 
 mice receiving MBP–CTLs were clinically
normal and experienced no weight loss.
The clinical signs described previously are very distinct
from those seen in CD4
 
 
 
 T cell–mediated disease. Histo-
logic analyses shown in (Fig. 3) also revealed striking differ-
ences between MBP-specific CTL-mediated autoimmune
disease and EAE in both the distribution and type of lesions
in the CNS. Lesions of clinically affected mice that received
MBP–CTLs were confined to the brain and involved small
blood vessels and the surrounding nervous tissue. These le-
sions were most frequent within the white matter of the
cerebellum (Fig. 3 B), but widely scattered, focal involve-
ment of gray (Fig. 3 J) and white matter of the brain stem,
midbrain, and cerebral cortex was also observed. Focal in-
flammation of the meninges with involvement of adjacent
nervous tissue occurred in some severely affected animals.
Spinal cord lesions were not seen in this series of animals.
The distribution of lesions in mice receiving MBP–CTLs at
various times post disease onset is summarized in Table I.
The average number of lesions in each anatomical com-
partment per slide did not vary significantly between mice
at different time points after disease onset with the cerebel-
lum having an average of six independent lesions per slide,
the brain stem with two, the midbrain with four, and the
cerebral cortex with two lesions per slide.
The vascular lesions in MBP-specific CTL-mediated dis-
ease involved capillaries and venules and consisted of
perivascular cuffing with rare disruption of the vascular
wall. The perivascular cuffs were composed of mixtures of
lymphocytes, macrophages, and a few neutrophils (Fig. 3
C). Inflammatory cells were focally marginated to the
prominent endothelial surface of cuffed vessels. The
changes seen in nervous tissue surrounding these affected
vessels were consistent with focal cytotoxic or ischemic in-
jury, although blood clots were not observed. These
changes included the presence of degenerative, necrotic,
and apoptotic cells (Fig. 3, D, G, and H) and loss of stain-
ing intensity (Fig. 3, B and F). Few inflammatory cells were
present outside of the perivascular cuff. Vacuolation of the
surrounding nervous tissue was common and consisted of
demyelination and cytoplasmic swelling (Fig. 3, F, G, and
J). Astrogliosis was occasionally noted in tissues surround-
ing affected vessels (Fig. 3 L) although in a few instances
perivascular injury manifests as a loss of all nucleated cells.
Brain tissues from control mice were histologically normal
(Fig. 3, A, E, I, and K). Examination of lung, liver, kidney,
Figure 1. MBP-specific CD8  cytotoxic T cells are present in wild-
type mice. (A) T cell clones derived from C3H wild-type mice express an
 /   TCR as well as CD8. All MBP79-87 T cell clones isolated from
C3H and C3H.shi mice were of the CD8  TCR  /   lineage. Data is
shown for the T cell clone used for disease transfer experiments. (B)
MBP-specific CD8  T cells derived from wild-type mice lyse MBP-
expressing target cells and (C) target cells coated with MBP79-87 peptide
in a similar dose response as T cell clones derived from C3H.shi mice in a
standard 51Cr release assay. An effector to target (E/T) ratio of 10:1 was
used for the peptide dose response. Data shown is representative of six in-
dependent MBP-specific T cell clones isolated from C3H wild-type mice
and 10 T cell clones isolated from C3H.shi mice.
Figure 2. MBP-specific CTLs isolated from C3H wild-type mice trans-
fer CNS autoimmunity. (A) Mean clinical score of recipient mice after
transfer of MBP–CTL or Vaccinia-specific CTLs (VAC–CTL) into C3H,
C3H.scid, or C3H.shi  recipient mice. (B) MBP–CTLs induced severe
weight loss in recipient mice expressing endogenous MBP. The mean
clinical score and weight loss is the average of three independent experi-
ments using the same T cell clone. Of two independent T cell clones stud-
ied, both induced similar CNS disease. Incidence of disease after transfer
of MBP–CTLs into recipient mice was 17/19 in C3H, 12/13 in C3H.scid,
0/15 in C3H.shi, and 0/14 after transfer of VAC–CTLs into C3H. 
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and myocardium from affected and control mice revealed
no significant lesions.
 
Effector Mechanism of MBP-specific CTL-mediated CNS Au-
toimmunity.
 
The major differences between the pathology
described here and that seen in EAE are the predominance
of lesions in the brain versus the spinal cord, the general
lack of inflammation (except that directly associated with
vascular walls) and the severe demyelination and perivascu-
lar cell death suggesting a cytotoxic or ischemic injury. It is
likely that some of these differences are due to different ef-
fector mechanisms used by CD8
 
  versus CD4  T cells. To
begin to address effector mechanisms in MBP-specific
CTL-mediated disease, we assessed the requirements for
IFN- , TNF- , and Fas–FasL interactions. Disease was in-
duced in recipient mice by intrathecally coinjecting MBP–
CTLs with and without neutralizing reagents specific for
IFN-  and TNF- . Intrathecal transfer of MBP–CTLs
alone induced a potent CNS autoimmune disease (Fig. 4
A). Clinical signs appear more rapidly after intrathecal ver-
sus intravenous transfer, presumably because the T cells do
not have to traffic to the CNS from the periphery. Coin-
jecting a neutralizing Ab to IFN-  with MBP–CTLs sig-
nificantly reduced severity of disease compared with con-
trol mice (Fig. 4 B), indicating that IFN-  plays an
important role in CD8  T cells specific for MBP (MBP–
CTL)–mediated CNS autoimmune disease. In contrast to
the results with IFN- , coinjection of TNFR:Fc fusion
protein with MBP–CTLs had no effect on disease course
compared with mice receiving isotype-matched control
Abs (Fig. 4 C). MBP–CTLs also do not depend on Fas–
FasL signaling as CNS autoimmunity was induced in
C3H.lpr mice that was indistinguishable from wild-type
C3H mice in time course and severity (Fig. 4 D).
Discussion
The role of CD8  T cells in MS is not known. The
question is of considerable interest because significant num-
Figure 3. Histologic analysis of  brain  from control
(VAC–CTLs transferred) and clinically affected (MBP–
CTLs transferred) mice. All sections were stained with
H&E unless otherwise noted. (A) Section of cerebellum
from a control mouse. The darkly stained nuclei of the
granular layer outline the central white matter. (B) Multi-
ple vessels within the cerebellar white matter of an affected
mouse are prominent due to perivascular cuffing. Loss of
staining intensity of the surrounding tissue is evident. The
arrow designates a vessel shown at a higher magnification
in C. (C) Venule with a perivascular cuff composed of
lymphocytes and macrophages. The arrow indicates one of
several inflammatory cells marginated to the endothelium.
(D) Apoptotic granular cell nuclei (arrows) in a zone pe-
ripheral to an involved venule similar to those in B. (E)
Section of cerebellum from a control mouse stained with
LFB. (F) LFB-stained section of an affected mouse demon-
strates myelin loss in an area similar to that in B. (G) LFB-
stained section of white matter showing loss of myelin
around an axon remnant (large arrow) and an apoptotic
glial cell nucleus (small arrow). (H) Crystal Violet–stained
section demonstrates fragments of nuclear debris (arrows)
in a focus of cerebellar white matter adjacent to an affected
vessel. (I) Section of normal gray matter from a control
mouse. (J) Section of gray matter from an affected mouse
showing perivascular cuffing and vacuolation. (K) Immu-
nohistochemical detection of GFAP demonstrates a solitary
astrocyte (arrow) adjacent to a vessel in the gray matter of a
control mouse. (L) GFAP staining of a serial section to that
shown in J demonstrates marked perivascular astrogliosis.
Sections are shown at original magnification: 20  (A, B,
E, F, I, J, K, and L) or original magnification: 100  (C, D,
G, and H). The perivascular lesions shown are highly rep-
resentative of lesions found in all anatomical compartments
in all affected mice.
Table I. Location of Lesions After Intravenous Transfer of
MBP-specific CTLs
Days after
disease onset
Cerebral
cortex Midbrain
Brain
stem Cerebellum
Preonset 0/4 0/4 0/4 0/4
1–4 4/4 4/4 3/4 4/4
5–8 2/4 3/4 4/4 4/4
9–14 1/3 3/3 2/3 2/3
Data shown are the number of mice per time point with lesions in each
anatomical compartment. Preonset mice were analyzed 4 d after transfer
and were asymptomatic. Mice in all other groups had a clinical score of
a two or greater. See paper for average number of lesions per brain
section. 4–6 serial sections of each cross-section were analyzed.673 Huseby et al.
bers of CD8  T cells of unknown function and antigen
specificity are present in MS plaques (3, 4, 8). Our results
demonstrate that MBP-specific CD8  T cells can function
as effector cells to induce CNS autoimmune disease in
mice. Demonstrating a pathogenic role for CD8  T cells
in CNS autoimmunity contrasts with observations made in
EAE that suggest that CD8  T cells inhibit the induction
of CNS autoimmunity or alter the clinical course of disease
(17–19). Finding divergent roles for CD8  T cells in CNS
autoimmunity suggests that functionally distinct subsets of
CD8  T cells contribute to disease in different ways. TGF-
 –expressing CD8  T cells appear to function as regulatory
cells (19) while our results indicate that IFN-  producing
MBP-specific CD8  T cells induce severe CNS autoim-
munity. This hypothesis has a direct corollary with the role
of CD4  T cells in autoimmune disease. CD25 CD4  T
cells of undefined antigen specificity perform a regulatory
function in inhibiting autoimmunity (25, 26) while CD4 
T cells specific for CNS antigens function as effector cells
in inducing EAE.
The disease mediated by adoptive transfer of CD8 
MBP-specific T cells described here is characterized by
very different clinical signs and CNS pathology than classic
EAE mediated by transfer of CD4  T cells. C3H mice
have been considered fairly resistant to EAE induced by ac-
tive immunization, however, adoptive transfer of CD4 
Th1 MBP-specific T cell lines into C3H mice results in
classic EAE (27). These differences between CD4 T cell–
and CTL-mediated EAE may be due to recognition of dif-
ferent cell types within the CNS by CD4  and CD8  T
cells and/or the different effector mechanisms employed by
CD4  versus CD8  T cells. The MBP–CTL-mediated dis-
ease described here is independent of CD4  T cells as well
as nonspecific CD8  T cells, as shown by the induction of
disease in C3H.scid  recipients. This result indicates that
MBP-specific CTLs can directly induce CNS autoimmu-
nity by interacting with MHC class I molecules presenting
the MBP epitope within the CNS and not by activating
endogenous myelin-specific CD4  T cells. Interestingly,
there are some reports of “atypical” EAE in some EAE-
resistant mouse strains immunized with certain PLP pep-
tides that exhibits some similarities to the CTL-mediated
disease described here (28, 29). T cells mediating this atyp-
ical EAE were not characterized and it would be interesting
to determine if they were CD4  or CD8  T cells. In hu-
man autoimmune disease, both CD4  and CD8  T cells
may contribute to disease, such that the pathology reflects
the activities of both types of effector cells.
CD8  T cell–mediated CNS autoimmunity is largely in-
hibited by neutralizing IFN-  activity. IFN-  may func-
tion to increase MHC class I expression which is extremely
limited in the CNS but is upregulated on resident cells by
exposure to IFN-  (30, 31). IFN-  may also promote de-
myelination through activation of macrophage and micro-
glia or by a deleterious effect on oligodendrocytes as de-
scribed for transgenic mice that express IFN-  under the
control of the MBP promoter (32). In contrast to the de-
pendence on IFN-  of CTL-mediated disease, IFN-  is a
protective cytokine in CD4  T cell–mediated EAE (33).
Interestingly, clinical trials of IFN-  in MS resulted in sig-
nificant exacerbation of symptoms in patients receiving
IFN-  as compared with controls (34) suggesting a stronger
parallel for IFN-  activity to CD8  T cell-mediated CNS
autoimmunity than CD4  T cell–mediated EAE.
In addition to IFN- , TNF-  and Fas appear to play
disparate roles in CD4  versus CD8  T cell–mediated
CNS autoimmunity. Neutralizing TNF-  activity had no
effect on CD8  T cell–mediated CNS autoimmune dis-
ease course. This result differs from the amelioration of
disease that occurs when TNF-  activity is neutralized in
EAE (35), and may be more similar to MS in which an es-
sential role for TNF-  has not been established (36, 37).
CD8  T cell–mediated CNS autoimmunity is also inde-
pendent of Fas–FasL interactions, while these interactions
have been shown to influence EAE in some mouse models
(38, 39).
The observation that CD4  and CD8  T cells employ
distinct effector mechanisms within the CNS may have im-
Figure 4. Mechanism of MBP-specific CTL-medi-
ated autoimmunity. Mean clinical scores are shown for
recipient mice after intrathecal transfer of MBP–CTLs.
Recipient mice are (A) C3H, C3H.scid, or C3H.shi
mice, (B) C3H mice coinjected with anti–IFN-  or
control Ab, (C) C3H recipients coinjected with
TNFR:Fc fusion protein or control Ab, and (D) C3H
or C3H.lpr mice. These experiments have been re-
peated twice. Incidence of disease was 35/43 for C3H
mice; 14/19 for C3H.scid mice; 0/24 for C3H.shi; 14/
18 for C3H plus anti-IFN- ; 15/17 for C3H plus
hamster IgG; 7/9 for C3H plus TNFR:Fc; 7/10 for
C3H plus human IgG; and 9/10 for C3H.lpr mice.674 Myelin-specific CD8  T Cells Induce CNS Autoimmunity
portant implications for understanding the pathogenesis of
MS. MS exhibits heterogeneity in clinical course and CNS
lesions and it has been difficult to formulate a unifying hy-
pothesis that accounts for this heterogeneity. Recent histo-
logical studies have categorized the different types of MS
lesions into separate patterns or groups. These efforts led to
the suggestion that the heterogeneity in pathology and
clinical outcome in MS patients reflects fundamentally dif-
ferent disease mechanisms (40). The MBP–CTL-mediated
model that we describe here provides experimental evi-
dence for this idea. The pathology observed in the MBP–
CTL model is most similar to that of Pattern IV described
by Lucchinetti et al. (41) for three patients with primary
progressive MS. In these patients, inflammatory lesions
centered on veins and venules and oligodendrocyte death is
suggested that is reminiscent of virus or toxin-induced de-
myelination. Patients exhibiting pattern IV pathology may
share a common pathogenic mechanism that includes
CD8  lymphocytes. Not all primary progressive MS pa-
tients exhibit this pattern, however, and most patients with
primary progressive MS have numerous lesions in the spi-
nal cord rather than the predominance of lesions in the
brain seen in MBP-specific CTL-mediated disease. Thus,
the CTL-mediated model, like CD4  T cell–mediated
EAE, is valuable in exploring the pathogenic potential and
effector mechanisms of different T cell subsets but does not
recapitulate all of the features of human disease.
One reason that accurate animal models of MS are diffi-
cult to generate is that the low precursor frequency of both
CD4  and CD8  myelin-specific T cells in healthy animals
requires artificial stimuli to induce disease and these stimuli
tend to focus on activation of one particular T cell subset.
Multiple factors are likely to be involved in triggering MS
and variation in these factors may preferentially activate dif-
ferent types of myelin-specific T cells in different patients.
Predisposing conditions for MS could include perturbations
that impair the efficiency of tolerance induction for either
MHC class I– or MHC class II–restricted T cells specific
for myelin antigens. The type of perturbation may vary
among patients such that the precursor frequency of one
class of autoreactive T cells may increase more than another
class. Therefore, identifying all of the cell types that can
contribute to disease as well as the conditions under which
these cells may be activated is essential to understand the
pathogenesis of MS.
Our results now implicate CD8  MBP-specific CTLs as
well as CD4  T cells as potential mediators of CNS au-
toimmune disease. Importantly, our data indicate that the
disease mediated by MBP-specific CTLs is distinct from
CD4  T cell–mediated disease, supporting the idea that
preferential activation of one T cell subset may emphasize
different aspects of MS. The MBP–CTL-mediated model
may be particularly useful in delineating events occurring
during the initial stages of MS. Widespread inflammation in
the CNS is a common feature of chronic MS, however, it
has been suggested that demyelination may be triggered by
an initial perivascular lymphocyte infiltration (40, 42). Sim-
ilar to the perivascular infiltrates in the myelin-specific
CD8  T cell model, CD8  T cells present in MS lesions
exhibit perivascular localization (3, 4). Endothelial cells as
well as resident phagocytic perivascular cells (43) may be
able to present MBP epitopes to CTLs via a cross-presenta-
tion pathway (44) as both cell types constitutively express
MHC class I molecules. Even though endothelial cells and
phagocytic antigen presenting cells do not synthesize MBP,
cell-associated antigens phagocytosed by antigen presenting
cells are processed through the MHC class I pathway (44).
Thus, perivascular injury mediated by myelin-specific
CD8  T cells may recapitulate events that occur during
particular stages of MS that have not been accessible for
study in other animal models.
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